Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia.
Rusyn L, Reinartz S, Nikiforov A, Mikhael N, Vom Stein A, Kohlhas V, Bloehdorn J, Stilgenbauer S, Lohneis P, Buettner R, Robrecht S, Fischer K, Pallasch C, Hallek M, Nguyen PH, Seeger-Nukpezah T. Rusyn L, et al. Among authors: lohneis p. Leukemia. 2022 Jul;36(7):1794-1805. doi: 10.1038/s41375-022-01586-1. Epub 2022 May 6. Leukemia. 2022. PMID: 35523865 Free PMC article.
The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma.
Loeser H, Kraemer M, Gebauer F, Bruns C, Schröder W, Zander T, Persa OD, Alakus H, Hoelscher A, Buettner R, Lohneis P, Quaas A. Loeser H, et al. Among authors: lohneis p. Oncoimmunology. 2019 Feb 27;8(5):e1581546. doi: 10.1080/2162402X.2019.1581546. eCollection 2019. Oncoimmunology. 2019. PMID: 31069143 Free PMC article.
Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma.
Gebauer F, Krämer M, Bruns C, Schlößer HA, Thelen M, Lohneis P, Schröder W, Zander T, Alakus H, Buettner R, Loeser H, Quaas A. Gebauer F, et al. Among authors: lohneis p. J Cancer Res Clin Oncol. 2020 Sep;146(9):2319-2327. doi: 10.1007/s00432-020-03295-7. Epub 2020 Jun 26. J Cancer Res Clin Oncol. 2020. PMID: 32592066 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 33140819
Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.
Kohlhaas V, Blakemore SJ, Al-Maarri M, Nickel N, Pal M, Roth A, Hövelmeyer N, Schäfer SC, Knittel G, Lohneis P, Nikolic M, Wiederstein JL, Franitza M, Georgomonolis T, Reinart N, Herling M, Herling C, Hartmann EM, Rosenwald A, Klapper W, Büttner R, Moia R, Rossi D, Boldorini R, Gaidano G, Frenzel LP, Reinhardt HC, Brüning JC, Hallek M, Krüger M, Peifer M, Pallasch CP, Wunderlich FT. Kohlhaas V, et al. Among authors: lohneis p. Blood. 2021 Feb 4;137(5):646-660. doi: 10.1182/blood.2020005734. Blood. 2021. PMID: 33538798 Free article.
Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies.
Flümann R, Hansen J, Pelzer BW, Nieper P, Lohmann T, Kisis I, Riet T, Kohlhas V, Nguyen PH, Peifer M, Abedpour N, Bosco G, Thomas RK, Kochanek M, Knüfer J, Jonigkeit L, Beleggia F, Holzem A, Büttner R, Lohneis P, Meinel J, Ortmann M, Persigehl T, Hallek M, Calado DP, Chmielewski M, Klein S, Göthert JR, Chapuy B, Zevnik B, Wunderlich FT, von Tresckow B, Jachimowicz RD, Melnick AM, Reinhardt HC, Knittel G. Flümann R, et al. Among authors: lohneis p. Blood Cancer Discov. 2023 Jan 6;4(1):78-97. doi: 10.1158/2643-3230.BCD-22-0007. Blood Cancer Discov. 2023. PMID: 36346827 Free PMC article.
Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors.
Borchmann S, Selenz C, Lohmann M, Ludwig H, Gassa A, Brägelmann J, Lohneis P, Meder L, Mattlener J, Breid S, Nill M, Fassunke J, Wisdom AJ, Compes A, Gathof B, Alakus H, Kirsch D, Hekmat K, Büttner R, Reinhardt HC, Hallek M, Ullrich RT. Borchmann S, et al. Among authors: lohneis p. J Immunother Cancer. 2022 Oct;10(10):e004781. doi: 10.1136/jitc-2022-004781. J Immunother Cancer. 2022. PMID: 36223955 Free PMC article.
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I.
Brägelmann J, Lorenz C, Borchmann S, Nishii K, Wegner J, Meder L, Ostendorp J, Ast DF, Heimsoeth A, Nakasuka T, Hirabae A, Okawa S, Dammert MA, Plenker D, Klein S, Lohneis P, Gu J, Godfrey LK, Forster J, Trajkovic-Arsic M, Zillinger T, Haarmann M, Quaas A, Lennartz S, Schmiel M, D'Rozario J, Thomas ES, Li H, Schmitt CA, George J, Thomas RK, von Karstedt S, Hartmann G, Büttner R, Ullrich RT, Siveke JT, Ohashi K, Schlee M, Sos ML. Brägelmann J, et al. Among authors: lohneis p. Nat Commun. 2021 Sep 17;12(1):5505. doi: 10.1038/s41467-021-25728-8. Nat Commun. 2021. PMID: 34535668 Free PMC article.
70 results